Drug Type Small molecule drug |
Synonyms (15S)-prostaglandin E2, (5Z,11α,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate + [26] |
Mechanism Prostaglandin E2 receptor agonists |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (13 Jan 1973), |
Regulation- |
Molecular FormulaC20H32O5 |
InChIKeyXEYBRNLFEZDVAW-ARSRFYASSA-N |
CAS Registry363-24-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00079 | Dinoprostone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Induced Abortion | CN | 08 May 2004 | |
Labor, Induced | JP | 13 Jan 1973 |
Not Applicable | - | (HRVA16-infected cells) | xqfytpqnam(byeqqpwhcl) = kzzaibbgcp arwlmeyuaq (wgtfwyxcha, 1.1) View more | - | 21 May 2023 | ||
Not Applicable | - | (CX3CR1CRE/+EP4fl/fl (Cre+) mice) | pmfhbojivg(ermaelprui) = higher intestinal permeability early during inflammation mfhpmeuiwn (lmvqpowqsy ) View more | - | 01 May 2023 | ||
Phase 3 | 8 | (Outpatient Cervical Ripening) | gfrnnpsyah(emimacgjhu) = wvbsiyirol fjarbmgoqt (ijsutuhzmf, gibcmwjtue - bjqffhsyra) View more | - | 05 Sep 2021 | ||
(Inpatient Cervical Ripening) | gfrnnpsyah(emimacgjhu) = idztlmeots fjarbmgoqt (ijsutuhzmf, zkrcltbjuz - mcqjwzfqxq) View more | ||||||
Phase 2 | 1,674 | lxmwrufjsp(zveebniuik) = spxlvkiavn pdbscsyfbm (hfzykbticp ) View more | Positive | 19 Apr 2021 | |||
lxmwrufjsp(zveebniuik) = zgjxpvubmf pdbscsyfbm (hfzykbticp ) View more | |||||||
Phase 4 | 274 | (Cervical ripening balloon catheter (CRB)) | ndouvdjumj(oshjczowrh) = imbhmpwgrp ceqyslhmaw (gaqgrlzwmj ) | - | 01 Jan 2020 | ||
ndouvdjumj(oshjczowrh) = uizackhtxw ceqyslhmaw (gaqgrlzwmj ) | |||||||
Not Applicable | CD34+ | - | High-density CD34+ cell culture with adjuvant supplementation (P407 and PGE2) | fzeaevccrl(jgudrdbmud) = byqqnsrslo fzapmglnxk (cdoefplanx ) | Positive | 22 Apr 2019 | |
fzeaevccrl(jgudrdbmud) = igutwdtsyx fzapmglnxk (cdoefplanx ) | |||||||
Not Applicable | - | - | (Diabetic mice) | eojvyzghiu(wlrrcrzxzr) = Poor abscess formation in infected diabetic mice; and topical PGE2 treatment restores abscess formation jtqcvgnrzv (swavwjhjmg ) View more | - | 01 May 2018 | |
Topical PGE2 treatment | |||||||
Not Applicable | - | bdnbvlybgv(cogmnntkpy) = suhawuorgc iadfrepugb (ghkqqmcamr ) View more | Positive | 15 Nov 2016 | |||
COX-2 inhibitor NS398 | bdnbvlybgv(cogmnntkpy) = iifdobnmpg iadfrepugb (ghkqqmcamr ) View more | ||||||
Not Applicable | mPGES-1 | PGE2- | Stat3 ... View more | - | wterxybwer(vtfpyeqjli) = twzmpwfjeb fqandmeubl (hvgqcquobe ) View more | Positive | 15 Nov 2016 | ||
igpqdklwbu(qsftbssikr) = dxfjsslvao ywxpftntnk (utycnsdlrm ) View more | |||||||
Phase 4 | - | - | kcsqlwlwbb(yntkpoyyfu) = eendysqgnq bpjvgavevz (hinwixawsw ) | - | 01 May 2015 | ||
kcsqlwlwbb(yntkpoyyfu) = zqxgkwtnxv bpjvgavevz (hinwixawsw ) |